Tricor, Lofibra tablets (fenofibrate) dosing, indications ...

Dosage Forms & Strengths ; TriCor tablet. 48mg; 145mg ; Lofibra tablet. 54mg; 160mg ; Fenoglide tablet. 40mg; 120mg ; Triglide tablet. 160mg ; Lipofen capsule. 50mg ... ForYou News&Perspective Drugs&Diseases CME&Education Academy Video DecisionPoint Edition: English Medscape English Deutsch Español Français Português UKNew Univadis LogIn SignUpIt'sFree! EnglishEdition Medscape English Deutsch Español Français Português UKNew Univadis X UnivadisfromMedscape Register LogIn NoResults NoResults ForYou News&Perspective Drugs&Diseases CME&Education Academy Video DecisionPoint close PleaseconfirmthatyouwouldliketologoutofMedscape. Ifyoulogout,youwillberequiredtoenteryourusernameandpasswordthenexttimeyouvisit. Logout Cancel https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9yZWZlcmVuY2UubWVkc2NhcGUuY29tL2RydWcvdHJpY29yLWxvZmlicmEtdGFibGV0cy1mZW5vZmlicmF0ZS0zNDI0NTE= processing.... Drugs&Diseasesfenofibrate(Rx)BrandandOtherNames:Tricor,Lofibratablets,more...Fenoglide,Lipofen,TriglideClasses:FibricAcidAgentsShareEmailPrintFeedbackCloseFacebookTwitterLinkedInWhatsApp SectionsSectionsfenofibrateDosing&UsesInteractionsAdverseEffectsWarningsPregnancyPharmacologyImagesPatientHandoutFormularyDosing&UsesAdultPediatricGeriatricDosageForms&StrengthsTriCortablet48mg145mgLofibratablet54mg160mgFenoglidetablet40mg120mgTriglidetablet160mgLipofencapsule50mg150mgTriCorHypercholesterolemia,mixeddyslipidemia:Initially,145mgPOqDayHypertriglyceridemia:Initially,48-145mgPOqDayTitrateq4-8weekuptonomorethan145mgPOqDayTriglideHypercholesterolemia,MixedDyslipidemia:initial160mgPOqDayHypertriglyceridemia:50-160mgPOqDayinitiallyLipofenHypercholesterolemia,MixedDyslipidemia:initial150mgPOqDayHypertriglyceridemia:initial50-150mgPOqDayLofibratabletsHypercholesterolemia,MixedDyslipidemia:160mgPOqDayHypertriglyceridemia:54-160mgPOqDayFenoglideHypercholesterolemia,MixedDyslipidemia:120mgPOqDayHypertriglyceridemia:40-120mgPOqDayDosingConsiderationsOverdosemanagementSymptomsincludeGIdistressTreatmentissupportiveDosingModificationsRenalimpairmentTriCor(CrCl<50mL/min):48mg/dayinitially;evaluatebeforeincreasedoseTriglide:Initial,50mg/dayLipofen:Initial,nomorethan50mg/dayLofibratablets:Initial,54mg/dayFenoglide:Initial,40mg/dayAdministrationTriCor,Triglide,andLofibratabletscanbetakenwithoutregardtomealsLipofen:TakewithmealsSafetyandefficacynotestablishedTriCorHypercholesterolemia,mixeddyslipidemia,hypertriglyceridemiaInitial:48mg/day;evaluatebeforeincreasedoseTriglideHypercholesterolemia,mixeddyslipidemia,hypertriglyceridemiaInitial:50mg/dayLipofenHypercholesterolemia,mixeddyslipidemia,hypertriglyceridemiaInitial:Nomorethan50mg/dayLofibratabletsHypercholesterolemia,mixeddyslipidemia,hypertriglyceridemiaInitial:54mg/dayFenoglideHypercholesterolemia,mixeddyslipidemia,hypertriglyceridemiaInitial:40mg/dayNext:InteractionsInteractionCheckerEnteradrugnameandfenofibrateNoResults  NoInteractionsFoundInteractionsFoundContraindicatedSerious-UseAlternativeSignificant-MonitorCloselyMinorAllInteractionsSortBy:SeverityName  Contraindicated(0)Serious-UseAlternative(14)abametapirabametapirwillincreasetheleveloreffectoffenofibratebyaffectinghepatic/intestinalenzymeCYP3A4metabolism.AvoidorUseAlternateDrug.For2weeksafterabametapirapplication,avoidtakingdrugsthatareCYP3A4substrates.Ifnotfeasible,avoiduseofabametapir.apalutamideapalutamidewilldecreasetheleveloreffectoffenofibratebyaffectinghepatic/intestinalenzymeCYP3A4metabolism.AvoidorUseAlternateDrug.Coadministrationofapalutamide,astrongCYP3A4inducer,withdrugsthatareCYP3A4substratescanresultinlowerexposuretothesemedications.Avoidorsubstituteanotherdrugforthesemedicationswhenpossible.Evaluateforlossoftherapeuticeffectifmedicationmustbecoadministered.Adjustdoseaccordingtoprescribinginformationifneeded.atorvastatinfenofibrate,atorvastatin. Eitherincreaseseffectsoftheotherbypharmacodynamicsynergism.AvoidorUseAlternateDrug.FenofibratemayfurtherincreaseriskforrhabdomyolysiswhenaddedtooptimalstatinregimentofurtherdecreaseTGandincreaseHDLs.colchicinecolchicine,fenofibrate. Eitherincreasestoxicityoftheotherbypharmacodynamicsynergism.AvoidorUseAlternateDrug.Increasedriskofrhabdomyolysis(inclafatality).fexinidazolefexinidazolewillincreasetheleveloreffectoffenofibratebyaffectinghepatic/intestinalenzymeCYP3A4metabolism.AvoidorUseAlternateDrug.FexinidazoleinhibitsCYP3A4.CoadministrationmayincreaseriskforadverseeffectsofCYP3A4substrates.fluvastatinfenofibrate,fluvastatin. Eitherincreaseseffectsoftheotherbypharmacodynamicsynergism.AvoidorUseAlternateDrug.FenofibratemayfurtherincreaseriskforrhabdomyolysiswhenaddedtooptimalstatinregimentofurtherdecreaseTGandincreaseHDLs.idelalisibidelalisibwillincreasetheleveloreffectoffenofibratebyaffectinghepatic/intestinalenzymeCYP3A4metabolism.AvoidorUseAlternateDrug.IdelalisibisastrongCYP3Ainhibitor;avoidcoadministrationwithsensitiveCYP3Asubstrateslovastatinfenofibrate,lovastatin. Eitherincreaseseffectsoftheotherbypharmacodynamicsynergism.AvoidorUseAlternateDrug.FenofibratemayfurtherincreaseriskforrhabdomyolysiswhenaddedtooptimalstatinregimentofurtherdecreaseTGandincreaseHDLs.Donotexceed20mg/dayoflovastatin.pitavastatinfenofibrate,pitavastatin. Eitherincreaseseffectsoftheotherbypharmacodynamicsynergism.AvoidorUseAlternateDrug.FenofibratemayfurtherincreaseriskforrhabdomyolysiswhenaddedtooptimalstatinregimentofurtherdecreaseTGandincreaseHDLs.pravastatinfenofibrate,pravastatin. Eitherincreaseseffectsoftheotherbypharmacodynamicsynergism.AvoidorUseAlternateDrug.FenofibratemayfurtherincreaseriskforrhabdomyolysiswhenaddedtooptimalstatinregimentofurtherdecreaseTGandincreaseHDLs.rosuvastatinfenofibrate,rosuvastatin. Eitherincreaseseffectsoftheotherbypharmacodynamicsynergism.AvoidorUseAlternateDrug.FenofibratemayfurtherincreaseriskforrhabdomyolysiswhenaddedtooptimalstatinregimentofurtherdecreaseTGandincreaseHDLs.simvastatinfenofibrate,simvastatin. Eitherincreaseseffectsoftheotherbypharmacodynamicsynergism.AvoidorUseAlternateDrug.FenofibratemayfurtherincreaseriskforrhabdomyolysiswhenaddedtooptimalstatinregimentofurtherdecreaseTGandincreaseHDLs.tucatinibtucatinibwillincreasetheleveloreffectoffenofibratebyaffectinghepatic/intestinalenzymeCYP3A4metabolism.AvoidorUseAlternateDrug.AvoidconcomitantuseoftucatinibwithCYP3Asubstrates,whereminimalconcentrationchangesmayleadtoseriousorlife-threateningtoxicities.Ifunavoidable,reduceCYP3Asubstratedoseaccordingtoproductlabeling.voxelotorvoxelotorwillincreasetheleveloreffectoffenofibratebyaffectinghepatic/intestinalenzymeCYP3A4metabolism.AvoidorUseAlternateDrug.VoxelotorincreasessystemicexposureofsensitiveCYP3A4substrates.AvoidcoadministrationwithsensitiveCYP3A4substrateswithanarrowtherapeuticindex.ConsiderdosereductionofthesensitiveCYP3A4substrate(s)ifunabletoavoid.MonitorClosely(38)belzutifanbelzutifanwilldecreasetheleveloreffectoffenofibratebyaffectinghepatic/intestinalenzymeCYP3A4metabolism.ModifyTherapy/MonitorClosely.IfunabletoavoidcoadministrationofbelzutifanwithsensitiveCYP3A4substrates,considerincreasingthesensitiveCYP3A4substratedoseinaccordancewithitsprescribinginformation.cannabidiolcannabidiolwillincreasetheleveloreffectoffenofibratebyOther(seecomment).ModifyTherapy/MonitorClosely.CannabidiolmaypotentiallyinhibitUGT1A9activity.ConsiderreducingthedosewhenconcomitantlyusingUGT1A9substrates.cenobamatecenobamatewilldecreasetheleveloreffectoffenofibratebyaffectinghepatic/intestinalenzymeCYP3A4metabolism.ModifyTherapy/MonitorClosely.IncreasedoseofCYP3A4substrate,asneeded,whencoadministeredwithcenobamate.chlorpropamidefenofibrateincreaseseffectsofchlorpropamidebyplasmaproteinbindingcompetition.UseCaution/Monitor.Hypoglycemia;increasedriskinhypoalbuminemia.cholestyraminecholestyraminedecreaseslevelsoffenofibratebyinhibitionofGIabsorption.Appliesonlytooralformofbothagents.UseCaution/Monitor.cholicacidfenofibrateincreasestoxicityofcholicacidbydecreasingelimination.ModifyTherapy/MonitorClosely.Avoidconcomitantuseofinhibitorsofthebilesalteffluxpump(BSEP).Mayexacerbateaccumulationofconjugatedbilesaltsintheliverandresultinclinicalsymptoms.Ifconcomitantuseisnecessary,monitorserumtransaminasesandbilirubin.crofelemercrofelemerincreaseslevelsoffenofibratebyaffectinghepatic/intestinalenzymeCYP3A4metabolism.UseCaution/Monitor.CrofelemerhasthepotentialtoinhibitCYP3A4atconcentrationsexpectedinthegut;unlikelytoinhibitsystemicallybecauseminimallyabsorbed.cyclosporinefenofibrateincreaseslevelsofcyclosporinebyunspecifiedinteractionmechanism.UseCaution/Monitor.dabrafenibdabrafenibwilldecreasetheleveloreffectoffenofibratebyaffectinghepatic/intestinalenzymeCYP3A4metabolism.ModifyTherapy/MonitorClosely.elagolixelagolixdecreaseslevelsoffenofibratebyaffectinghepatic/intestinalenzymeCYP3A4metabolism.ModifyTherapy/MonitorClosely.Elagolixisaweak-to-moderateCYP3A4inducer.MonitorCYP3Asubstratesifcoadministered.ConsiderincreasingCYP3Asubstratedoseifneeded.elvitegravir/cobicistat/emtricitabine/tenofovirDFelvitegravir/cobicistat/emtricitabine/tenofovirDFincreaseslevelsoffenofibratebyaffectinghepatic/intestinalenzymeCYP3A4metabolism.ModifyTherapy/MonitorClosely.CobicistatisaCYP3A4inhibitor;contraindicatedwithCYP3A4substratesforwhichelevatedplasmaconcentrationsareassociatedwithseriousand/orlife-threateningevents.fedratinibfedratinibwillincreasetheleveloreffectoffenofibratebyaffectinghepatic/intestinalenzymeCYP3A4metabolism.UseCaution/Monitor.AdjustdoseofdrugsthatareCYP3A4substratesasnecessary.fosphenytoinfosphenytoinwilldecreasetheleveloreffectoffenofibratebyaffectinghepatic/intestinalenzymeCYP3A4metabolism.UseCaution/Monitor.glimepiridefenofibrateincreaseseffectsofglimepiridebyplasmaproteinbindingcompetition.UseCaution/Monitor.Hypoglycemia;increasedriskinhypoalbuminemia.glipizidefenofibrateincreaseseffectsofglipizidebyplasmaproteinbindingcompetition.UseCaution/Monitor.Hypoglycemia;increasedriskinhypoalbuminemia.glyburidefenofibrateincreaseseffectsofglyburidebyplasmaproteinbindingcompetition.UseCaution/Monitor.Hypoglycemia;increasedriskinhypoalbuminemia.iloperidoneiloperidoneincreaseslevelsoffenofibratebyaffectinghepatic/intestinalenzymeCYP3A4metabolism.UseCaution/Monitor.Iloperidoneisatime-dependentCYP3AinhibitorandmayleadtoincreasedplasmalevelsofdrugspredominantlyeliminatedbyCYP3A4.insulinaspartfenofibrateincreaseseffectsofinsulinaspartbyunspecifiedinteractionmechanism.UseCaution/Monitor.Hypoglycemia;increasedriskinhypoalbuminemia.insulindegludecfenofibrate,insulindegludec. Eitherincreaseseffectsoftheotherbypharmacodynamicsynergism.UseCaution/Monitor.Bothdrugsdecreasebloodglucose.insulindegludec/insulinaspartfenofibrate,insulindegludec/insulinaspart. Eitherincreaseseffectsoftheotherbypharmacodynamicsynergism.UseCaution/Monitor.Bothdrugsdecreasebloodglucose.insulindetemirfenofibrateincreaseseffectsofinsulindetemirbyunspecifiedinteractionmechanism.UseCaution/Monitor.Hypoglycemia;increasedriskinhypoalbuminemia.insulinglarginefenofibrateincreaseseffectsofinsulinglarginebyunspecifiedinteractionmechanism.UseCaution/Monitor.Hypoglycemia;increasedriskinhypoalbuminemia.insulinglulisinefenofibrateincreaseseffectsofinsulinglulisinebyunspecifiedinteractionmechanism.UseCaution/Monitor.Hypoglycemia;increasedriskinhypoalbuminemia.insulininhaledfenofibrate,insulininhaled. Eitherincreaseseffectsoftheotherbypharmacodynamicsynergism.UseCaution/Monitor.Bothdrugsdecreasebloodglucose.insulinlisprofenofibrateincreaseseffectsofinsulinlisprobyunspecifiedinteractionmechanism.UseCaution/Monitor.Hypoglycemia;increasedriskinhypoalbuminemia.insulinNPHfenofibrateincreaseseffectsofinsulinNPHbyunspecifiedinteractionmechanism.UseCaution/Monitor.Hypoglycemia;increasedriskinhypoalbuminemia.insulinregularhumanfenofibrateincreaseseffectsofinsulinregularhumanbyunspecifiedinteractionmechanism.UseCaution/Monitor.Hypoglycemia;increasedriskinhypoalbuminemia.istradefyllineistradefyllinewillincreasetheleveloreffectoffenofibratebyaffectinghepatic/intestinalenzymeCYP3A4metabolism.UseCaution/Monitor.Istradefylline40mg/dayincreasedpeaklevelsandAUCofCYP3A4substratesinclinicaltrials.Thiseffectwasnotobservedwithistradefylline20mg/day.ConsiderdosereductionofsensitiveCYP3A4substrates.mavacamtenfenofibratewillincreasetheleveloreffectofmavacamtenbyaffectinghepaticenzymeCYP2C19metabolism.ModifyTherapy/MonitorClosely.InititiationofweakCYP2C19inhibitorsmayrequiredecreasedmavacamtendose.mitotanemitotanedecreaseslevelsoffenofibratebyaffectinghepatic/intestinalenzymeCYP3A4metabolism.UseCaution/Monitor.MitotaneisastronginducerofcytochromeP-4503A4;monitorwhencoadministeredwithCYP3A4substratesforpossibledosageadjustments.rucaparibrucaparibwillincreasetheleveloreffectoffenofibratebyaffectinghepatic/intestinalenzymeCYP3A4metabolism.ModifyTherapy/MonitorClosely.AdjustdosageofCYP3A4substrates,ifclinicallyindicated.stiripentolstiripentol,fenofibrate.affectinghepatic/intestinalenzymeCYP3A4metabolism.ModifyTherapy/MonitorClosely.StiripentolisaCYP3A4inhibitorandinducer.MonitorCYP3A4substratescoadministeredwithstiripentolforincreasedordecreasedeffects.CYP3A4substratesmayrequiredosageadjustment.tazemetostattazemetostatwilldecreasetheleveloreffectoffenofibratebyaffectinghepatic/intestinalenzymeCYP3A4metabolism.UseCaution/Monitor.tecovirimattecovirimatwilldecreasetheleveloreffectoffenofibratebyaffectinghepatic/intestinalenzymeCYP3A4metabolism.UseCaution/Monitor.TecovirimatisaweakCYP3A4inducer.MonitorsensitiveCYP3A4substratesforeffectivenessifcoadministered.tenofovirDFfenofibrateincreaseslevelsoftenofovirDFbydecreasingrenalclearance.UseCaution/Monitor.Increasedriskofmyopathy.tolazamidefenofibrateincreaseseffectsoftolazamidebyplasmaproteinbindingcompetition.UseCaution/Monitor.Hypoglycemia;increasedriskinhypoalbuminemia.tolbutamidefenofibrateincreaseseffectsoftolbutamidebyplasmaproteinbindingcompetition.UseCaution/Monitor.Hypoglycemia;increasedriskinhypoalbuminemia.warfarinfenofibratewillincreasetheleveloreffectofwarfarinbyaffectinghepaticenzymeCYP2C9/10metabolism.ModifyTherapy/MonitorClosely.MechanismofinteractionmaybecausedbyCYP2C9inhibitionandprotein-bindingdisplacement.Minor(5)colestipolcolestipoldecreaseslevelsoffenofibratebyinhibitionofGIabsorption.Appliesonlytooralformofbothagents.Minor/SignificanceUnknown.ezetimibefenofibrateincreaseslevelsofezetimibebyunspecifiedinteractionmechanism.Minor/SignificanceUnknown.levoketoconazolelevoketoconazolewillincreasetheleveloreffectoffenofibratebyaffectinghepatic/intestinalenzymeCYP3A4metabolism.Minor/SignificanceUnknown.octacosanoloctacosanolincreaseseffectsoffenofibratebypharmacodynamicsynergism.Minor/SignificanceUnknown.ribociclibribociclibwillincreasetheleveloreffectoffenofibratebyaffectinghepatic/intestinalenzymeCYP3A4metabolism.Minor/SignificanceUnknown.abametapirSerious-UseAlternative(1)abametapirwillincreasetheleveloreffectoffenofibratebyaffectinghepatic/intestinalenzymeCYP3A4metabolism.AvoidorUseAlternateDrug.For2weeksafterabametapirapplication,avoidtakingdrugsthatareCYP3A4substrates.Ifnotfeasible,avoiduseofabametapir.apalutamideSerious-UseAlternative(1)apalutamidewilldecreasetheleveloreffectoffenofibratebyaffectinghepatic/intestinalenzymeCYP3A4metabolism.AvoidorUseAlternateDrug.Coadministrationofapalutamide,astrongCYP3A4inducer,withdrugsthatareCYP3A4substratescanresultinlowerexposuretothesemedications.Avoidorsubstituteanotherdrugforthesemedicationswhenpossible.Evaluateforlossoftherapeuticeffectifmedicationmustbecoadministered.Adjustdoseaccordingtoprescribinginformationifneeded.atorvastatinSerious-UseAlternative(1)fenofibrate,atorvastatin. Eitherincreaseseffectsoftheotherbypharmacodynamicsynergism.AvoidorUseAlternateDrug.FenofibratemayfurtherincreaseriskforrhabdomyolysiswhenaddedtooptimalstatinregimentofurtherdecreaseTGandincreaseHDLs.belzutifanMonitorClosely(1)belzutifanwilldecreasetheleveloreffectoffenofibratebyaffectinghepatic/intestinalenzymeCYP3A4metabolism.ModifyTherapy/MonitorClosely.IfunabletoavoidcoadministrationofbelzutifanwithsensitiveCYP3A4substrates,considerincreasingthesensitiveCYP3A4substratedoseinaccordancewithitsprescribinginformation.cannabidiolMonitorClosely(1)cannabidiolwillincreasetheleveloreffectoffenofibratebyOther(seecomment).ModifyTherapy/MonitorClosely.CannabidiolmaypotentiallyinhibitUGT1A9activity.ConsiderreducingthedosewhenconcomitantlyusingUGT1A9substrates.cenobamateMonitorClosely(1)cenobamatewilldecreasetheleveloreffectoffenofibratebyaffectinghepatic/intestinalenzymeCYP3A4metabolism.ModifyTherapy/MonitorClosely.IncreasedoseofCYP3A4substrate,asneeded,whencoadministeredwithcenobamate.chlorpropamideMonitorClosely(1)fenofibrateincreaseseffectsofchlorpropamidebyplasmaproteinbindingcompetition.UseCaution/Monitor.Hypoglycemia;increasedriskinhypoalbuminemia.cholestyramineMonitorClosely(1)cholestyraminedecreaseslevelsoffenofibratebyinhibitionofGIabsorption.Appliesonlytooralformofbothagents.UseCaution/Monitor.cholicacidMonitorClosely(1)fenofibrateincreasestoxicityofcholicacidbydecreasingelimination.ModifyTherapy/MonitorClosely.Avoidconcomitantuseofinhibitorsofthebilesalteffluxpump(BSEP).Mayexacerbateaccumulationofconjugatedbilesaltsintheliverandresultinclinicalsymptoms.Ifconcomitantuseisnecessary,monitorserumtransaminasesandbilirubin.colchicineSerious-UseAlternative(1)colchicine,fenofibrate. Eitherincreasestoxicityoftheotherbypharmacodynamicsynergism.AvoidorUseAlternateDrug.Increasedriskofrhabdomyolysis(inclafatality).colestipolMinor(1)colestipoldecreaseslevelsoffenofibratebyinhibitionofGIabsorption.Appliesonlytooralformofbothagents.Minor/SignificanceUnknown.crofelemerMonitorClosely(1)crofelemerincreaseslevelsoffenofibratebyaffectinghepatic/intestinalenzymeCYP3A4metabolism.UseCaution/Monitor.CrofelemerhasthepotentialtoinhibitCYP3A4atconcentrationsexpectedinthegut;unlikelytoinhibitsystemicallybecauseminimallyabsorbed.cyclosporineMonitorClosely(1)fenofibrateincreaseslevelsofcyclosporinebyunspecifiedinteractionmechanism.UseCaution/Monitor.dabrafenibMonitorClosely(1)dabrafenibwilldecreasetheleveloreffectoffenofibratebyaffectinghepatic/intestinalenzymeCYP3A4metabolism.ModifyTherapy/MonitorClosely.elagolixMonitorClosely(1)elagolixdecreaseslevelsoffenofibratebyaffectinghepatic/intestinalenzymeCYP3A4metabolism.ModifyTherapy/MonitorClosely.Elagolixisaweak-to-moderateCYP3A4inducer.MonitorCYP3Asubstratesifcoadministered.ConsiderincreasingCYP3Asubstratedoseifneeded.elvitegravir/cobicistat/emtricitabine/tenofovirDFMonitorClosely(1)elvitegravir/cobicistat/emtricitabine/tenofovirDFincreaseslevelsoffenofibratebyaffectinghepatic/intestinalenzymeCYP3A4metabolism.ModifyTherapy/MonitorClosely.CobicistatisaCYP3A4inhibitor;contraindicatedwithCYP3A4substratesforwhichelevatedplasmaconcentrationsareassociatedwithseriousand/orlife-threateningevents.ezetimibeMinor(1)fenofibrateincreaseslevelsofezetimibebyunspecifiedinteractionmechanism.Minor/SignificanceUnknown.fedratinibMonitorClosely(1)fedratinibwillincreasetheleveloreffectoffenofibratebyaffectinghepatic/intestinalenzymeCYP3A4metabolism.UseCaution/Monitor.AdjustdoseofdrugsthatareCYP3A4substratesasnecessary.fexinidazoleSerious-UseAlternative(1)fexinidazolewillincreasetheleveloreffectoffenofibratebyaffectinghepatic/intestinalenzymeCYP3A4metabolism.AvoidorUseAlternateDrug.FexinidazoleinhibitsCYP3A4.CoadministrationmayincreaseriskforadverseeffectsofCYP3A4substrates.fluvastatinSerious-UseAlternative(1)fenofibrate,fluvastatin. Eitherincreaseseffectsoftheotherbypharmacodynamicsynergism.AvoidorUseAlternateDrug.FenofibratemayfurtherincreaseriskforrhabdomyolysiswhenaddedtooptimalstatinregimentofurtherdecreaseTGandincreaseHDLs.fosphenytoinMonitorClosely(1)fosphenytoinwilldecreasetheleveloreffectoffenofibratebyaffectinghepatic/intestinalenzymeCYP3A4metabolism.UseCaution/Monitor.glimepirideMonitorClosely(1)fenofibrateincreaseseffectsofglimepiridebyplasmaproteinbindingcompetition.UseCaution/Monitor.Hypoglycemia;increasedriskinhypoalbuminemia.glipizideMonitorClosely(1)fenofibrateincreaseseffectsofglipizidebyplasmaproteinbindingcompetition.UseCaution/Monitor.Hypoglycemia;increasedriskinhypoalbuminemia.glyburideMonitorClosely(1)fenofibrateincreaseseffectsofglyburidebyplasmaproteinbindingcompetition.UseCaution/Monitor.Hypoglycemia;increasedriskinhypoalbuminemia.idelalisibSerious-UseAlternative(1)idelalisibwillincreasetheleveloreffectoffenofibratebyaffectinghepatic/intestinalenzymeCYP3A4metabolism.AvoidorUseAlternateDrug.IdelalisibisastrongCYP3Ainhibitor;avoidcoadministrationwithsensitiveCYP3AsubstratesiloperidoneMonitorClosely(1)iloperidoneincreaseslevelsoffenofibratebyaffectinghepatic/intestinalenzymeCYP3A4metabolism.UseCaution/Monitor.Iloperidoneisatime-dependentCYP3AinhibitorandmayleadtoincreasedplasmalevelsofdrugspredominantlyeliminatedbyCYP3A4.insulinaspartMonitorClosely(1)fenofibrateincreaseseffectsofinsulinaspartbyunspecifiedinteractionmechanism.UseCaution/Monitor.Hypoglycemia;increasedriskinhypoalbuminemia.insulindegludecMonitorClosely(1)fenofibrate,insulindegludec. Eitherincreaseseffectsoftheotherbypharmacodynamicsynergism.UseCaution/Monitor.Bothdrugsdecreasebloodglucose.insulindegludec/insulinaspartMonitorClosely(1)fenofibrate,insulindegludec/insulinaspart. Eitherincreaseseffectsoftheotherbypharmacodynamicsynergism.UseCaution/Monitor.Bothdrugsdecreasebloodglucose.insulindetemirMonitorClosely(1)fenofibrateincreaseseffectsofinsulindetemirbyunspecifiedinteractionmechanism.UseCaution/Monitor.Hypoglycemia;increasedriskinhypoalbuminemia.insulinglargineMonitorClosely(1)fenofibrateincreaseseffectsofinsulinglarginebyunspecifiedinteractionmechanism.UseCaution/Monitor.Hypoglycemia;increasedriskinhypoalbuminemia.insulinglulisineMonitorClosely(1)fenofibrateincreaseseffectsofinsulinglulisinebyunspecifiedinteractionmechanism.UseCaution/Monitor.Hypoglycemia;increasedriskinhypoalbuminemia.insulininhaledMonitorClosely(1)fenofibrate,insulininhaled. Eitherincreaseseffectsoftheotherbypharmacodynamicsynergism.UseCaution/Monitor.Bothdrugsdecreasebloodglucose.insulinlisproMonitorClosely(1)fenofibrateincreaseseffectsofinsulinlisprobyunspecifiedinteractionmechanism.UseCaution/Monitor.Hypoglycemia;increasedriskinhypoalbuminemia.insulinNPHMonitorClosely(1)fenofibrateincreaseseffectsofinsulinNPHbyunspecifiedinteractionmechanism.UseCaution/Monitor.Hypoglycemia;increasedriskinhypoalbuminemia.insulinregularhumanMonitorClosely(1)fenofibrateincreaseseffectsofinsulinregularhumanbyunspecifiedinteractionmechanism.UseCaution/Monitor.Hypoglycemia;increasedriskinhypoalbuminemia.istradefyllineMonitorClosely(1)istradefyllinewillincreasetheleveloreffectoffenofibratebyaffectinghepatic/intestinalenzymeCYP3A4metabolism.UseCaution/Monitor.Istradefylline40mg/dayincreasedpeaklevelsandAUCofCYP3A4substratesinclinicaltrials.Thiseffectwasnotobservedwithistradefylline20mg/day.ConsiderdosereductionofsensitiveCYP3A4substrates.levoketoconazoleMinor(1)levoketoconazolewillincreasetheleveloreffectoffenofibratebyaffectinghepatic/intestinalenzymeCYP3A4metabolism.Minor/SignificanceUnknown.lovastatinSerious-UseAlternative(1)fenofibrate,lovastatin. Eitherincreaseseffectsoftheotherbypharmacodynamicsynergism.AvoidorUseAlternateDrug.FenofibratemayfurtherincreaseriskforrhabdomyolysiswhenaddedtooptimalstatinregimentofurtherdecreaseTGandincreaseHDLs.Donotexceed20mg/dayoflovastatin.mavacamtenMonitorClosely(1)fenofibratewillincreasetheleveloreffectofmavacamtenbyaffectinghepaticenzymeCYP2C19metabolism.ModifyTherapy/MonitorClosely.InititiationofweakCYP2C19inhibitorsmayrequiredecreasedmavacamtendose.mitotaneMonitorClosely(1)mitotanedecreaseslevelsoffenofibratebyaffectinghepatic/intestinalenzymeCYP3A4metabolism.UseCaution/Monitor.MitotaneisastronginducerofcytochromeP-4503A4;monitorwhencoadministeredwithCYP3A4substratesforpossibledosageadjustments.octacosanolMinor(1)octacosanolincreaseseffectsoffenofibratebypharmacodynamicsynergism.Minor/SignificanceUnknown.pitavastatinSerious-UseAlternative(1)fenofibrate,pitavastatin. Eitherincreaseseffectsoftheotherbypharmacodynamicsynergism.AvoidorUseAlternateDrug.FenofibratemayfurtherincreaseriskforrhabdomyolysiswhenaddedtooptimalstatinregimentofurtherdecreaseTGandincreaseHDLs.pravastatinSerious-UseAlternative(1)fenofibrate,pravastatin. Eitherincreaseseffectsoftheotherbypharmacodynamicsynergism.AvoidorUseAlternateDrug.FenofibratemayfurtherincreaseriskforrhabdomyolysiswhenaddedtooptimalstatinregimentofurtherdecreaseTGandincreaseHDLs.ribociclibMinor(1)ribociclibwillincreasetheleveloreffectoffenofibratebyaffectinghepatic/intestinalenzymeCYP3A4metabolism.Minor/SignificanceUnknown.rosuvastatinSerious-UseAlternative(1)fenofibrate,rosuvastatin. Eitherincreaseseffectsoftheotherbypharmacodynamicsynergism.AvoidorUseAlternateDrug.FenofibratemayfurtherincreaseriskforrhabdomyolysiswhenaddedtooptimalstatinregimentofurtherdecreaseTGandincreaseHDLs.rucaparibMonitorClosely(1)rucaparibwillincreasetheleveloreffectoffenofibratebyaffectinghepatic/intestinalenzymeCYP3A4metabolism.ModifyTherapy/MonitorClosely.AdjustdosageofCYP3A4substrates,ifclinicallyindicated.simvastatinSerious-UseAlternative(1)fenofibrate,simvastatin. Eitherincreaseseffectsoftheotherbypharmacodynamicsynergism.AvoidorUseAlternateDrug.FenofibratemayfurtherincreaseriskforrhabdomyolysiswhenaddedtooptimalstatinregimentofurtherdecreaseTGandincreaseHDLs.stiripentolMonitorClosely(1)stiripentol,fenofibrate.affectinghepatic/intestinalenzymeCYP3A4metabolism.ModifyTherapy/MonitorClosely.StiripentolisaCYP3A4inhibitorandinducer.MonitorCYP3A4substratescoadministeredwithstiripentolforincreasedordecreasedeffects.CYP3A4substratesmayrequiredosageadjustment.tazemetostatMonitorClosely(1)tazemetostatwilldecreasetheleveloreffectoffenofibratebyaffectinghepatic/intestinalenzymeCYP3A4metabolism.UseCaution/Monitor.tecovirimatMonitorClosely(1)tecovirimatwilldecreasetheleveloreffectoffenofibratebyaffectinghepatic/intestinalenzymeCYP3A4metabolism.UseCaution/Monitor.TecovirimatisaweakCYP3A4inducer.MonitorsensitiveCYP3A4substratesforeffectivenessifcoadministered.tenofovirDFMonitorClosely(1)fenofibrateincreaseslevelsoftenofovirDFbydecreasingrenalclearance.UseCaution/Monitor.Increasedriskofmyopathy.tolazamideMonitorClosely(1)fenofibrateincreaseseffectsoftolazamidebyplasmaproteinbindingcompetition.UseCaution/Monitor.Hypoglycemia;increasedriskinhypoalbuminemia.tolbutamideMonitorClosely(1)fenofibrateincreaseseffectsoftolbutamidebyplasmaproteinbindingcompetition.UseCaution/Monitor.Hypoglycemia;increasedriskinhypoalbuminemia.tucatinibSerious-UseAlternative(1)tucatinibwillincreasetheleveloreffectoffenofibratebyaffectinghepatic/intestinalenzymeCYP3A4metabolism.AvoidorUseAlternateDrug.AvoidconcomitantuseoftucatinibwithCYP3Asubstrates,whereminimalconcentrationchangesmayleadtoseriousorlife-threateningtoxicities.Ifunavoidable,reduceCYP3Asubstratedoseaccordingtoproductlabeling.voxelotorSerious-UseAlternative(1)voxelotorwillincreasetheleveloreffectoffenofibratebyaffectinghepatic/intestinalenzymeCYP3A4metabolism.AvoidorUseAlternateDrug.VoxelotorincreasessystemicexposureofsensitiveCYP3A4substrates.AvoidcoadministrationwithsensitiveCYP3A4substrateswithanarrowtherapeuticindex.ConsiderdosereductionofthesensitiveCYP3A4substrate(s)ifunabletoavoid.warfarinMonitorClosely(1)fenofibratewillincreasetheleveloreffectofwarfarinbyaffectinghepaticenzymeCYP2C9/10metabolism.ModifyTherapy/MonitorClosely.MechanismofinteractionmaybecausedbyCYP2C9inhibitionandprotein-bindingdisplacement. PreviousNext:AdverseEffects >10%IncreasedLFT's(doserelated,3-13%)1-10%Respiratorydisorder(6%)Abdominalpain(5%)Backpain(3%)CPKincreased(3%)Headache(3%)Constipation(2%)Nausea(2%)Rhinitis(2%)PostmarketingReportsMusclepainMyopathiesMyositisDiarrheaFlatulencePancreatitisPepticulcerCholelithiasisCNSdepressionDysrhythmiasPeripheralvasculardiseasePulmonaryembolusRenaldamageRashAnemiaLeukopenia PreviousNext:Warnings ContraindicationsKnownhypersensitivitySevererenalimpairment,includingthosewithend-stagerenaldiseaseandthosereceivingdialysisActiveliverdiseaseGallbladderdiseaseNursingmothersCautionsCholelithiasisreportedwithuse;discontinueifgallstonesdetectedupongallbladderstudiesRaremyopathy,myositis,orrhabdomyolysisreportedwithuse;monitorIncreaseinhepatictransaminasesreported;discontinueifenzymelevelspersist3timesabovetheupperlimitofnormalReversiblyincreasesserumcreatininelevels;considermonitoringrenalfunctioninpatientsatriskforrenalimpairmentThrombocytopeniaandagranulocytosisreported;monitorbloodcountsperiodicallyduringthefirstyearoftherapyAssociatedwithpulmonaryembolismanddeepvenousthrombosis;usecautioninpatientswithriskfactorsforVTEConcomitantusewithoralanticoagulants(monitorandadjustwarfarindoseprn)MayfurtherincreaseriskforrhabdomyolysiswhenaddedtooptimalHMG-CoAreductaseinhibitorregimentofurtherdecreaseTGandincreaseHDLsParadoxicaldecreasesinHDLcholesterol(HDL-C)levelreportedRuleoutsecondarycausesofhyperlipidemiabeforeinitiatingtherapyWithdrawtherapyifnoadequateresponseseenafter2-3monthsUsewithcautionintheelderly;doseadjustmentsmaybenecessaryFenofibrateincreasescholesterolexcretionintobile,leadingtoriskofcholelithiasis;performgallbladderstudiesifcholelithiasissuspectedFibricacidderivativesasmonotherapyorincombinationwithsimvastatinhavenotbeenshowntosignificantlyreducecardiovascularmortalityinmajorclinicalstudies PreviousNext:Pregnancy&Lactation PregnancyLimitedavailabledatawithfenofibrateuseinpregnantwomenareinsufficienttodetermineadrug-associatedriskofmajorbirthdefects,miscarriageoradversematernalorfetaloutcomesAnimaldataInanimalreproductionstudies,noevidenceofembryo-fetaltoxicitywasobservedwithoraladministrationinratsandrabbitsduringorganogenesisatdoseslessthanorequivalenttothemaximumrecommendedclinicaldoseof120mgdaily,basedonbodysurfacearea(mg/m2)Adversereproductiveoutcomesoccurredathigherdosesinpresenceofmaternaltoxicity;drugshouldbeusedduringpregnancyonlyifpotentialbenefitjustifiespotentialrisktofetusLactationThereisnoavailableinformationonpresenceofdruginhumanmilk,effectsonthebreastfedinfant,oronmilkproduction;drugispresentinmilkofrats,andlikelytobepresentinhumanmilk;becauseofpotentialforseriousadversereactionsinbreastfedinfants,suchasdisruptionofinfantlipidmetabolism,womenshouldnotbreastfeedduringtreatmentandfor5daysafterfinaldosePregnancyCategoriesA:Generallyacceptable.Controlledstudiesinpregnantwomenshownoevidenceoffetalrisk.B:Maybeacceptable.Eitheranimalstudiesshownoriskbuthumanstudiesnotavailableoranimalstudiesshowedminorrisksandhumanstudiesdoneandshowednorisk.C:Usewithcautionifbenefitsoutweighrisks.Animalstudiesshowriskandhumanstudiesnotavailableorneitheranimalnorhumanstudiesdone.D:UseinLIFE-THREATENINGemergencieswhennosaferdrugavailable.Positiveevidenceofhumanfetalrisk.X:Donotuseinpregnancy.Risksinvolvedoutweighpotentialbenefits.Saferalternativesexist.NA:Informationnotavailable. PreviousNext:Pharmacology MechanismofActionIncreasesVLDLcatabolism,fattyacidoxidation,andeliminationoftriglyceriderichparticlesbyenhancingsynthesisoflipoproteinlipase,whichinturnresultsin30-60%decreaseintotalplasmatriglycerides;HDLmayincreasemodestlyinsomehypertriglyceridemicpatientsAbsorptionBioavailability:60-90%Onset:2wkPeakplasmatime:2-8hrDistributionDistributeswidelytomosttissuesProteinbound:99%MetabolismLiverMetabolites:Fenofibricacid(active),fenofibricacidglucuronide(activityunknown)EliminationHalf-life:20hr(10-35hrrange)Dialyzable:No(HD)Excretion:Urine(60-93%),feces(5-25%)PharmacogenomicsGenotypingpatientswithatherogenicdyslipidemiamayestablishwhowillbenefitmostfromfenofibricacidtherapytoincreaseHDL-CThreesingle-nucleotidepolymorphisms(SNPs)intheAPOA5regionhavebeenassociatedwithincreasesinHDL-C PreviousNext:Images BRAND FORM. UNITPRICE PILLIMAGE fenofibrateoral-160mgtabletfenofibrateoral-160mgtabletfenofibrateoral-160mgtabletfenofibrateoral-54mgtabletfenofibrateoral-160mgtabletfenofibrateoral-160mgtabletfenofibrateoral-120mgtabletfenofibrateoral-40mgtabletfenofibrateoral-54mgtabletfenofibrateoral-160mgtabletfenofibrateoral-54mgtabletfenofibrateoral-160mgtabletfenofibrateoral-160mgtabletfenofibrateoral-54mgtabletfenofibrateoral-54mgtabletfenofibrateoral-50mgcapsulefenofibrateoral-160mgtabletfenofibrateoral-54mgtabletfenofibrateoral-54mgtabletfenofibrateoral-150mgcapsulefenofibrateoral-54mgtabletfenofibrateoral-160mgtabletfenofibrateoral-54mgtabletLipofenoral-150mgcapsuleLipofenoral-50mgcapsuleFenoglideoral-40mgtabletFenoglideoral-120mgtabletCopyright©2010FirstDataBank,Inc. PreviousNext:PatientHandoutPrint FENOFIBRATE-ORAL (fen-oh-FYE-brate) COMMONBRANDNAME(S):Tricor,Triglide USES:Fenofibrateisusedalongwithaproperdiettohelplower"bad"cholesterolandfats(suchasLDL,triglycerides)andraise"good"cholesterol(HDL)intheblood.Itworksbyincreasingthenaturalsubstance(enzyme)thatbreaksdownfatsintheblood.Fenofibratebelongstoagroupofdrugsknownas"fibrates."Loweringtriglyceridesinpeoplewithveryhightriglyceridebloodlevelsmaydecreasetheriskofpancreasdisease(pancreatitis).However,fenofibratemightnotloweryourriskofaheartattackorstroke.Talktoyourdoctorabouttherisksandbenefitsoffenofibrate.Inadditiontoeatingaproperdiet(suchasalow-cholesterol/low-fatdiet),otherlifestylechangesthatmayhelpthismedicationworkbetterincludeexercising,losingweightifoverweight,andstoppingsmoking.Consultyourdoctorformoredetails. HOWTOUSE:Takethismedicationbymouthasdirectedbyyourdoctor,usuallyoncedaily.Fenofibratecomesindifferenttypesofcapsulesandtabletswhichprovidedifferentamountsofthemedication.Donotswitchbetweendifferentformsorbrandsofthismedicationunlessdirectedbyyourdoctor.Someformsofthisdrugshouldbetakenwithfoodbutothersmaybetakenwithorwithoutfood.Askyourpharmacistaboutyourbrandoffenofibrate.Itisimportanttotakethismedicationcorrectlysothatthedrughasthegreatestbenefit.Thedosageisbasedonyourmedicalconditionandresponsetotreatment.Ifyouarealsotakingcertainotherdrugstoloweryourcholesterol(bileacid-bindingresinssuchascholestyramineorcolestipol),takefenofibrateatleast1hourbeforeoratleast4to6hoursaftertakingthesemedications.Thesemedicationscanbindtofenofibrate,preventingyourbodyfromfullyabsorbingthedrug.Takethismedicationregularlytogetthemostbenefitfromit.Tohelpyouremember,takeitatthesametimeeachday.Donotincreaseyourdoseorusethisdrugmoreoftenorforlongerthanprescribed.Yourcholesterol/triglycerideslevelwillnotlowerfaster,andyourriskofsideeffectswillincrease.Keeptakingthismedicationevenifyoufeelwell.Mostpeoplewithhighcholesterol/triglyceridesdonotfeelsick.Itisveryimportanttocontinuetofollowyourdoctor'sadviceaboutdietandexercise.Itmaytakeupto2monthsbeforeyougetthefullbenefitofthismedication. SIDEEFFECTS:Rememberthatthismedicationhasbeenprescribedbecauseyourdoctorhasjudgedthatthebenefittoyouisgreaterthantheriskofsideeffects.Manypeopleusingthismedicationdonothaveserioussideeffects.Thismedicationmayrarelycausegallstonesandliverproblems.Ifyounoticeanyofthefollowingunlikelybutserioussideeffects,tellyourdoctorrightaway:nausea/vomitingthatdoesn'tstop,lossofappetite,stomach/abdominalpain,yellowingeyes/skin,darkurine.Thisdrugmayrarelycausemuscleproblems(whichcanrarelyleadtoaveryseriousconditioncalledrhabdomyolysis).Tellyourdoctorrightawayifyoudevelopanyofthesesymptoms:musclepain/tenderness/weakness(especiallywithfeverorunusualtiredness),signsofkidneyproblems(suchaschangeintheamountofurine).Rarely,thismedicationhascausedsevereloweringofHDL("good"cholesterol)levels.ThisistheoppositeofwhatshouldhappentoyourHDLlevels(paradoxicalreaction).YourHDLcholesterollevelsshouldbecheckedregularly.Keepallofyourlaboratoryappointments.Tellyourdoctorrightawayifyouhaveanyserioussideeffects,including:easybleeding/bruising,unusualtiredness.Getmedicalhelprightawayifyouhaveanyveryserioussideeffects,including:chestpain,suddenpain/redness/swellingusuallyintheleg,signsofinfection(suchassorethroatthatdoesn'tgoaway,fever,swollenlymphnodes,chills,cough).Averyseriousallergicreactiontothisdrugisrare.However,getmedicalhelprightawayifyounoticeanysymptomsofaseriousallergicreaction,including:rash,itching/swelling(especiallyoftheface/tongue/throat),severedizziness,troublebreathing.Thisisnotacompletelistofpossiblesideeffects.Ifyounoticeothereffectsnotlistedabove,contactyourdoctororpharmacist.IntheUS-Callyourdoctorformedicaladviceaboutsideeffects.YoumayreportsideeffectstoFDAat1-800-FDA-1088oratwww.fda.gov/medwatch.InCanada-Callyourdoctorformedicaladviceaboutsideeffects.YoumayreportsideeffectstoHealthCanadaat1-866-234-2345. PRECAUTIONS:Beforetakingfenofibrate,tellyourdoctororpharmacistifyouareallergictoit;ortoother"fibrates"(suchasfenofibricacid);orifyouhaveanyotherallergies.Thisproductmaycontaininactiveingredients(suchassoy),whichcancauseallergicreactionsorotherproblems.Talktoyourpharmacistformoredetails.Beforeusingthismedication,tellyourdoctororpharmacistyourmedicalhistory,especiallyof:kidneydisease,gallbladderdisease,liverdisease(suchasbiliarycholangitis,hepatitis),alcoholuse.Beforehavingsurgery,tellyourdoctorordentistaboutalltheproductsyouuse(includingprescriptiondrugs,nonprescriptiondrugs,andherbalproducts).Duringpregnancy,thismedicationshouldbeusedonlywhenclearlyneeded.Discusstherisksandbenefitswithyourdoctor.Itisunknownifthismedicationpassesintobreastmilk.Becauseofthepossiblerisktotheinfant,breast-feedingisnotrecommendedwhileusingthisdrugandfor5daysafterstoppingthedrug.Consultyourdoctorbeforebreast-feeding. DRUGINTERACTIONS:SeealsoHowtoUsesection.Druginteractionsmaychangehowyourmedicationsworkorincreaseyourriskforserioussideeffects.Thisdocumentdoesnotcontainallpossibledruginteractions.Keepalistofalltheproductsyouuse(includingprescription/nonprescriptiondrugsandherbalproducts)andshareitwithyourdoctorandpharmacist.Donotstart,stop,orchangethedosageofanymedicineswithoutyourdoctor'sapproval.Someproductsthatmayinteractwiththisdruginclude:"bloodthinners"(suchaswarfarin).Fenofibrateisverysimilartofenofibricacid.Donotusemedicationscontainingfenofibricacidwhileusingfenofibrate. OVERDOSE:Ifsomeonehasoverdosedandhasserioussymptomssuchaspassingoutortroublebreathing,call911.Otherwise,callapoisoncontrolcenterrightaway.USresidentscancalltheirlocalpoisoncontrolcenterat1-800-222-1222.Canadaresidentscancallaprovincialpoisoncontrolcenter. NOTES:Donotsharethismedicationwithothers.Laboratoryand/ormedicaltests(suchascholesterol/triglyceridelevels,kidney/liverfunctiontests,completebloodcount)shouldbeperformedperiodicallytomonitoryourprogressorcheckforsideeffects.Consultyourdoctorformoredetails.(SeealsoSideEffectssection.) MISSEDDOSE:Ifyoumissadose,takeitassoonasyouremember.Ifitisnearthetimeofthenextdose,skipthemisseddose.Takeyournextdoseattheregulartime.Donotdoublethedosetocatchup. STORAGE:Storeatroomtemperatureawayfromlightandmoisture.Differentbrandsofthismedicationhavedifferentstorageneeds.Checktheproductpackageforinstructionsonhowtostoreyourbrand,oraskyourpharmacist.Donotstoreinthebathroom.Keepallmedicationsawayfromchildrenandpets.Donotflushmedicationsdownthetoiletorpourthemintoadrainunlessinstructedtodoso.Properlydiscardthisproductwhenitisexpiredornolongerneeded.Consultyourpharmacistorlocalwastedisposalcompany. InformationlastrevisedAugust2021.Copyright(c)2022FirstDatabank,Inc. IMPORTANT:HOWTOUSETHISINFORMATION:ThisisasummaryanddoesNOThaveallpossibleinformationaboutthisproduct.Thisinformationdoesnotassurethatthisproductissafe,effective,orappropriateforyou.Thisinformationisnotindividualmedicaladviceanddoesnotsubstitutefortheadviceofyourhealthcareprofessional.Alwaysaskyourhealthcareprofessionalforcompleteinformationaboutthisproductandyourspecifichealthneeds. PreviousNext:FormularyFormularyPatientDiscountsAddingplansallowsyoutocompareformularystatustootherdrugsinthesameclass.Toviewformularyinformationfirstcreatealistofplans.Yourlistwillbesavedandcanbeeditedatanytime.CreateYourListofPlansAddingplansallowsyouto:Viewtheformularyandanyrestrictionsforeachplan.Manageandviewallyourplanstogether–evenplansindifferentstates.Compareformularystatustootherdrugsinthesameclass.Accessyourplanlistonanydevice–mobileordesktop. Theaboveinformationisprovidedforgeneral informationalandeducationalpurposesonly.Individualplansmayvary andformularyinformationchanges.Contacttheapplicableplan providerforthemostcurrentinformation. Viewexplanationsfortiersand restrictions Tier Description 1 Thisdrugisavailableatthelowestco-pay.Most commonly,thesearegenericdrugs. 2 Thisdrugisavailableatamiddlelevelco-pay.Most commonly,theseare"preferred"(onformulary)branddrugs. 3 Thisdrugisavailableatahigherlevelco-pay.Most commonly,theseare"non-preferred"branddrugs. 4 Thisdrugisavailableatahigherlevelco-pay.Most commonly,theseare"non-preferred"branddrugsorspecialty prescriptionproducts. 5 Thisdrugisavailableatahigherlevelco-pay.Most commonly,theseare"non-preferred"branddrugsorspecialty prescriptionproducts. 6 Thisdrugisavailableatahigherlevelco-pay.Most commonly,theseare"non-preferred"branddrugsorspecialty prescriptionproducts. NC NOTCOVERED–Drugsthatarenot coveredbytheplan. Code Definition PA PriorAuthorizationDrugsthat requirepriorauthorization.Thisrestrictionrequiresthat specificclinicalcriteriabemetpriortotheapprovalofthe prescription. QL QuantityLimitsDrugsthat havequantitylimitsassociatedwitheachprescription.This restrictiontypicallylimitsthequantityofthedrugthatwill becovered. ST StepTherapyDrugsthathave steptherapyassociatedwitheachprescription.Thisrestriction typicallyrequiresthatcertaincriteriabemetpriorto approvalfortheprescription. OR OtherRestrictionsDrugsthat haverestrictionsotherthanpriorauthorization,quantity limits,andsteptherapyassociatedwitheachprescription. Plans SelectState: Alabama Alaska Arizona Arkansas California Colorado Connecticut Delaware DistrictofColumbia Florida Georgia Hawaii Idaho Illinois Indiana Iowa Kansas Kentucky Louisiana Maine Maryland Massachusetts Michigan Minnesota Mississippi Missouri Montana Nebraska Nevada NewHampshire NewJersey NewMexico NewYork NorthCarolina NorthDakota Ohio Oklahoma Oregon Pennsylvania PuertoRico RhodeIsland SouthCarolina SouthDakota Tennessee Texas Utah Vermont Virginia Washington WestVirginia Wisconsin Wyoming Done Non-MedicarePlans MedicarePlans Done CLOSE From: To: Therecipientwillreceivemoredetailsandinstructionstoaccessthisoffer. Byclickingsend,youacknowledgethatyouhavepermissiontoemailtherecipientwiththisinformation. Send From: To: Therecipientwillreceivemoredetailsandinstructionstoaccessthisoffer. Byclickingsend,youacknowledgethatyouhavepermissiontoemailtherecipientwiththisinformation. Send PreviousMedscapeprescriptiondrugmonographsarebasedonFDA-approvedlabelinginformation,unlessotherwisenoted,combinedwithadditionaldataderivedfromprimarymedicalliterature.[CLOSEWINDOW]SectionsfenofibrateDosing&UsesInteractionsAdverseEffectsWarningsPregnancyPharmacologyImagesPatientHandoutFormularyCloseWhatwouldyouliketoprint?Whatwouldyouliketoprint?PrintthissectionPrinttheentirecontentsofCloseDosingCalculator FindUsOn About AboutMedscape PrivacyPolicy EditorialPolicy Cookies DoNotSellMyPersonalInformation TermsofUse AdvertisingPolicy HelpCenter Membership BecomeaMember AboutYou ProfessionalInformation Newsletters&Alerts App Medscape WebMDNetwork MedscapeLiveEvents WebMD MedicineNet eMedicineHealth RxList WebMDCorporate Editions English Deutsch Español Français Português Allmaterialonthiswebsiteisprotectedbycopyright,Copyright©1994-2022byWebMDLLC.Thiswebsitealsocontainsmaterialcopyrightedby3rdparties. Close encodedsearchterm(fenofibrate(Tricor%2CLofibratablets))andfenofibrate(Tricor,Lofibratablets) WhattoReadNextonMedscape MedscapeConsult News&Perspective 25Drugs,DrugClassesAddedtoFDA'sSafetySignalList Antibiotics,AntidepressantsDominateNewFDAWatchList TakotsuboCardiomyopathyAfteranUpperandLowerEndoscopy Tools DrugInteractionChecker PillIdentifier Calculators Formulary DrugClass Slideshow MedscapeCardiologistWealth&DebtReport2021 Recommended 20022500032-overviewDiseases&Conditions Diseases&Conditions LipidManagementGuidelines 2003/viewarticle/965245 LipidManagementReview/TipsFromtheExperts:CVRiskReductionandCardiopreventionatItsFinest 1.5CME/CE/ABIMMOCCredits Youarebeingredirectedto MedscapeEducation Yes,takemethere 1.5CME/CE/ABIMMOC LipidManagementReview/TipsFromtheExperts:CVRiskReductionandCardiopreventionatItsFinest 2010/viewarticle/940625 FastFiveQuiz:LipidsManagement:HighHDLCholesterolLevels(Hyperalphalipoproteinemia) 2001/viewarticle/971442 ALookAheadtoACC2022:Late-BreakingClinicalTrialsinLipidManagement NeedaCurbsideConsult? SharecasesandquestionswithPhysiciansonMedscapeconsult. Share aCase